The CNS Challenge: Balancing Risk With Reward

Neuroscience is in the DNA of Worldwide Clinical Trials. Founded by a team of neuroscientists, Worldwide has worked in CNS since the late 1970s when the first cholinesterase inhibitors emerged as a cognitive therapeutic. Our breadth and depth of experience continues more than 40 years later, as we continue to innovate and adapt in our commitment to advancing research.

This desire is powered by the rigor of research experts who know what it takes to translate a lifesaving therapeutic solution into a compelling data set demonstrating efficacy and value. Because we understand that, in CNS indications, the success or failure of a compound rides on the quality of the end points, we are one of the only midsize CROs that has an in-house rater training team. Today, our Clinical Analytics, Training, and Surveillance group is fully integrated with the study team and systems in your clinical trial. We know patient needs, we know how to keep them safe, we know how to identify the appropriate end points, and we know how to manage the data to demonstrate your treatment’s effectiveness. We hold patient dignity and data integrity in balance.